Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Icon of the Seas: World's largest cruise ship to set sail from Miami
Labour defends roadside drug testing legislation
DOC spent nearly $500,000 to kill one stoat in Fiordland
Long flu season winds down in US
Zelensky counts on more Western defence aid for Ukraine in next two months
Judge declines to delay Trump hush money trial over publicity complaints
EDITORIAL: Sex offender checks must protect children, human rights
HBCU Xavier of New Orleans moves closer to establishing a medical school
London police say chemical attacker presumed dead
Finnish hacker imprisoned for accessing thousands of psychotherapy records and demanding ransoms
Movement of pilot's seat a focus of probe into LATAM Boeing flight, report says